ArticleThe American journal of pathology2002
Signature tau neuropathology in gray and white matter of corticobasal degeneration.
Article in The American journal of pathology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.
- Patterns of gray matter atrophy in atypical parkinsonism syndromes: a VBM meta-analysis.Brain and behavior · 2015Pooled it
- Integrating Metabolic, Perfusion, and Microstructural Parameters for Quantitative Neuroimaging in Rare Neurodegenerative Diseases: A Hybrid PET/MRI Approach.Diagnostics (Basel, Switzerland) · 2026Article
- Methods for studying the effects of phosphorylation patterns in proteins.Biochemical Society transactions · 2026Review
- Tau conformation, distribution and PET imaging correlations in progressive supranuclear palsy.Translational neurodegeneration · 2026Review
- Differences in the soluble and insoluble proteome between primary tauopathies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Primary retinal tauopathy: A tauopathy with a distinct molecular pattern.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Fiber-specific micro- and macroscopic white matter alterations in progressive supranuclear palsy and corticobasal syndrome.NPJ Parkinson's disease · 2023Article
- Antemortem network analysis of spreading pathology in autopsy-confirmed frontotemporal degeneration.Brain communications · 2023Article
- The effects of microglia on tauopathy progression can be quantified using Nexopathy in silico (Nexis) models.Scientific reports · 2022Article
- Tau interactome and RNA binding proteins in neurodegenerative diseases.Molecular neurodegeneration · 2022Review
- Recent advances in pre-clinical diagnosis of Alzheimer's disease.Metabolic brain disease · 2022Review
- Temporal Progression Patterns of Brain Atrophy in Corticobasal Syndrome and Progressive Supranuclear Palsy Revealed by Subtype and Stage Inference (SuStaIn).Frontiers in neurology · 2022Article
- Left Frontal White Matter Links to Rhythm Processing Relevant to Speech Production in Apraxia of Speech.Neurobiology of language (Cambridge, Mass.) · 2022Article
- Deep learning reveals disease-specific signatures of white matter pathology in tauopathies.Acta neuropathologica communications · 2021Article
- Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type.Translational psychiatry · 2021Article
- Cellular and pathological heterogeneity of primary tauopathies.Molecular neurodegeneration · 2021Review
- In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics.Acta neuropathologica · 2021Article
- Evaluation of [Brain communications · 2021Article
- Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.CNS drugs · 2020Review
- Clinical and pathologic features of cognitive-predominant corticobasal degeneration.Neurology · 2020Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Corticobasal degeneration (CBD) is an adult-onset progressive neurodegenerative disorder characterized by L-dopa-resistant rigidity, focal cortical deficits, and variable dementia. The neuropathological hallmark of CBD is the deposition of filamentous inclusions in neurons and glia composed of hyperphosphorylated tau with only four microtubule-binding repeats (4R-tau). To characterize the regional burden of tau pathology in CBD, we studied 12 brains with the neuropathological diagnosis of CBD using biochemical and histochemical techniques. Eleven brain regions were evaluated including gray and white matter from frontal, parietal, temporal, and occipital lobes and cerebellum as well as basal ganglia. Although the distribution of tau pathology was variable, neuropathological and biochemical data showed a similar burden of tau abnormalities in frontal, temporal, and parietal lobes and basal ganglia of both hemispheres. This included abundant, sarkosyl-insoluble 4R-tau in both gray and white matter of two or more of these cortical regions and basal ganglia, and to a lesser extent, cerebellar white matter. The insoluble tau pathology in gray and white matter showed overlapping but distinct phosphorylated epitopes suggesting cell-type and subcellular localization (ie, cell bodies versus cell processes)-specific differences in tau phosphorylation. In contrast, soluble tau was composed of normal 4R/3R-tau ratios indicating no gross abnormality in tau splicing. Thus, although clinically heterogeneous, CBD is a distinct lobar and basal ganglionic tauopathy with selective aggregation of 4R-tau.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.